Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 160

1.

Receptor Binding Assays and Drug Discovery.

Bylund DB, Enna SJ.

Adv Pharmacol. 2018;82:21-34. doi: 10.1016/bs.apha.2017.08.007. Epub 2017 Oct 15. Review.

PMID:
29413522
2.

Replicated, replicable and relevant-target engagement and pharmacological experimentation in the 21st century.

Kenakin T, Bylund DB, Toews ML, Mullane K, Winquist RJ, Williams M.

Biochem Pharmacol. 2014 Jan 1;87(1):64-77. doi: 10.1016/j.bcp.2013.10.024. Epub 2013 Nov 19. Review.

PMID:
24269285
3.

Quantitative versus qualitative data: the numerical dimensions of drug action.

Bylund DB, Toews ML.

Biochem Pharmacol. 2014 Jan 1;87(1):25-39. doi: 10.1016/j.bcp.2013.07.027. Epub 2013 Aug 8. Review.

PMID:
23933389
4.

Changes in postnatal norepinephrine alter alpha-2 adrenergic receptor development.

Sanders JD, Happe HK, Bylund DB, Murrin LC.

Neuroscience. 2011 Sep 29;192:761-72. doi: 10.1016/j.neuroscience.2011.06.045. Epub 2011 Jun 22.

5.

Radioligand binding methods for membrane preparations and intact cells.

Bylund DB, Toews ML.

Methods Mol Biol. 2011;746:135-64. doi: 10.1007/978-1-61779-126-0_8.

PMID:
21607856
6.

Differential effects of inescapable stress on locus coeruleus GRK3, alpha2-adrenoceptor and CRF1 receptor levels in learned helpless and non-helpless rats: a potential link to stress resilience.

Taneja M, Salim S, Saha K, Happe HK, Qutna N, Petty F, Bylund DB, Eikenburg DC.

Behav Brain Res. 2011 Aug 1;221(1):25-33. doi: 10.1016/j.bbr.2011.02.018. Epub 2011 Feb 17.

7.

Lack of effect of the alpha2C-adrenoceptor Del322-325 polymorphism on inhibition of cyclic AMP production in HEK293 cells.

Montgomery MD, Bylund DB.

Br J Pharmacol. 2010 Feb;159(4):820-30. doi: 10.1111/j.1476-5381.2009.00584.x. Epub 2010 Jan 28.

8.

Molecular modelling of subtypes (alpha(2A), alpha(2B) and alpha(2C)) of alpha(2)-adrenoceptors: a comparative study.

Balogh B, Szilágyi A, Gyires K, Bylund DB, Mátyus P.

Neurochem Int. 2009 Nov;55(6):355-61. doi: 10.1016/j.neuint.2009.05.004. Epub 2009 May 15.

PMID:
19447153
9.

Treatment with escitalopram but not desipramine decreases escape latency times in a learned helplessness model using juvenile rats.

Reed AL, Anderson JC, Bylund DB, Petty F, El Refaey H, Happe HK.

Psychopharmacology (Berl). 2009 Aug;205(2):249-59. doi: 10.1007/s00213-009-1535-2. Epub 2009 Apr 22.

PMID:
19387616
10.

Differential effects of neonatal norepinephrine lesions on immediate early gene expression in developing and adult rat brain.

Sanders JD, Happe HK, Bylund DB, Murrin LC.

Neuroscience. 2008 Dec 10;157(4):821-32. doi: 10.1016/j.neuroscience.2008.09.036. Epub 2008 Oct 1.

11.
12.

Juvenile rats in the forced-swim test model the human response to antidepressant treatment for pediatric depression.

Reed AL, Happe HK, Petty F, Bylund DB.

Psychopharmacology (Berl). 2008 Apr;197(3):433-41. doi: 10.1007/s00213-007-1052-0. Epub 2008 Jan 8.

PMID:
18180907
13.

The differential regulation of BDNF and TrkB levels in juvenile rats after four days of escitalopram and desipramine treatment.

Kozisek ME, Middlemas D, Bylund DB.

Neuropharmacology. 2008 Feb;54(2):251-7. Epub 2007 Aug 10.

PMID:
18048068
14.

Selecting selectivities and the neuropharmacology of antidepressant drug action: a commentary.

Bylund DB.

FASEB J. 2007 Nov;21(13):3417-8. No abstract available.

PMID:
17967928
15.

Alpha- and beta-adrenergic receptors: Ahlquist's landmark hypothesis of a single mediator with two receptors.

Bylund DB.

Am J Physiol Endocrinol Metab. 2007 Dec;293(6):E1479-81. Epub 2007 Oct 23. No abstract available.

16.

Brain-derived neurotrophic factor and its receptor tropomyosin-related kinase B in the mechanism of action of antidepressant therapies.

Kozisek ME, Middlemas D, Bylund DB.

Pharmacol Ther. 2008 Jan;117(1):30-51. Epub 2007 Aug 15. Review.

PMID:
17949819
17.

Pharmacological properties of the active metabolites of the antidepressants desipramine and citalopram.

Deupree JD, Montgomery MD, Bylund DB.

Eur J Pharmacol. 2007 Dec 8;576(1-3):55-60. Epub 2007 Aug 23.

18.

Childhood and adolescent depression: why do children and adults respond differently to antidepressant drugs?

Bylund DB, Reed AL.

Neurochem Int. 2007 Oct;51(5):246-53. Epub 2007 Jun 30. Review.

19.

Today's research, tomorrow's health: focus on pharmacogenomics.

Bylund DB, Kozisek ME, Montgomery MD, Reed AL.

Per Med. 2007 Aug;4(3):363-367. doi: 10.2217/17410541.4.3.363. No abstract available.

PMID:
29788667
20.

Appropriate dosing regimens for treating juvenile rats with desipramine for neuropharmacological and behavioral studies.

Kozisek ME, Deupree JD, Burke WJ, Bylund DB.

J Neurosci Methods. 2007 Jun 15;163(1):83-91. Epub 2007 Feb 22.

21.
22.

Differential effects of the tricyclic antidepressant desipramine on the density of adrenergic receptors in juvenile and adult rats.

Deupree JD, Reed AL, Bylund DB.

J Pharmacol Exp Ther. 2007 May;321(2):770-6. Epub 2007 Feb 9.

PMID:
17293562
23.

Possible involvement of alpha-2A adrenergic receptors in attention deficit hyperactivity disorder: radioligand binding and polymorphism studies.

Deupree JD, Smith SD, Kratochvil CJ, Bohac D, Ellis CR, Polaha J, Bylund DB; UNMC Collaborative ADHD Research Team.

Am J Med Genet B Neuropsychiatr Genet. 2006 Dec 5;141B(8):877-84.

PMID:
16917924
24.

Analysis of brain adrenergic receptors in dopamine-beta-hydroxylase knockout mice.

Sanders JD, Szot P, Weinshenker D, Happe HK, Bylund DB, Murrin LC.

Brain Res. 2006 Sep 13;1109(1):45-53. Epub 2006 Jul 18.

PMID:
16854392
25.

NIGMS-sponsored integrative and organ systems pharmacology: synopsis of the 2005 experience/anticipation of the 2006 short courses.

Bylund DB, Brunton LL, Cobbett PJ, Persky AM, Preusch PC.

Mol Interv. 2005 Dec;5(6):330-3. No abstract available.

PMID:
16394246
26.

Pharmacologic principles for combination therapy.

Toews ML, Bylund DB.

Proc Am Thorac Soc. 2005;2(4):282-9; discussion 290-1. Review.

PMID:
16267349
27.

Exploring the active site of phenylethanolamine N-methyltransferase with 3-hydroxyethyl- and 3-hydroxypropyl-7-substituted-1,2,3,4-tetrahydroisoquinolines.

Grunewald GL, Romero FA, Seim MR, Criscione KR, Deupree JD, Spackman CC, Bylund DB.

Bioorg Med Chem Lett. 2005 Feb 15;15(4):1143-7.

PMID:
15686930
28.

Alpha-2 adrenoceptor subtypes: are more better?

Bylund DB.

Br J Pharmacol. 2005 Jan;144(2):159-60. Review.

29.

Development of the norepinephrine transporter in the rat CNS.

Sanders JD, Happe HK, Bylund DB, Murrin LC.

Neuroscience. 2005;130(1):107-17.

PMID:
15561429
30.

Radioligand-binding methods for membrane preparations and intact cells.

Bylund DB, Deupree JD, Toews ML.

Methods Mol Biol. 2004;259:1-28.

PMID:
15250483
31.

Alpha-2 adrenergic receptor development in rat CNS: an autoradiographic study.

Happe HK, Coulter CL, Gerety ME, Sanders JD, O'Rourke M, Bylund DB, Murrin LC.

Neuroscience. 2004;123(1):167-78.

PMID:
14667451
32.

Adrenergic receptor genes: cDNA and genomic library construction.

Scofield MA, Deupree JD, Bylund DB.

Mol Biotechnol. 2002 Jun;21(2):171-97.

PMID:
12059116
33.
34.

Agonist-stimulated [35S]GTPgammaS autoradiography: optimization for high sensitivity.

Happe HK, Bylund DB, Murrin LC.

Eur J Pharmacol. 2001 Jun 22;422(1-3):1-13.

PMID:
11430907
35.

A robust GTP-induced shift in alpha(2)-adrenoceptor agonist affinity in tissue sections from rat brain.

Bylund DB, Gerety ME, Happe HK, Murrin LC.

J Neurosci Methods. 2001 Feb 15;105(2):159-66.

PMID:
11275272
36.

Radioligand saturation binding experiments over large concentration ranges.

Bylund DB, Murrin LC.

Life Sci. 2000 Nov 3;67(24):2897-911. Review.

PMID:
11133002
37.

Alpha(2)-adrenoceptor-stimulated GTP gamma S binding in rat brain: an autoradiographic study.

Happe HK, Bylund DB, Murrin LC.

Eur J Pharmacol. 2000 Jun 30;399(1):17-27.

PMID:
10876018
38.

Inverse agonism at alpha(2)-adrenoceptors in native tissue.

Murrin LC, Gerety ME, Happe HK, Bylund DB.

Eur J Pharmacol. 2000 Jun 16;398(2):185-91.

PMID:
10854829
39.

In vivo gene modification elucidates subtype-specific functions of alpha(2)-adrenergic receptors.

Kable JW, Murrin LC, Bylund DB.

J Pharmacol Exp Ther. 2000 Apr;293(1):1-7. Review.

PMID:
10734146
40.

Analyses of adrenergic receptor sequences.

Deupree JD, Scofield MA, Bylund DB.

Methods Mol Biol. 2000;126:53-72. Review. No abstract available.

PMID:
10685402
41.

Isolation of adrenergic receptor genes.

Scofield MA, Deupree JD, Bylund DB.

Methods Mol Biol. 2000;126:37-51. Review. No abstract available.

PMID:
10685401
42.

Construction of libraries for isolation of adrenergic receptor genes.

Scofield MA, Deupree JD, Bylund DB.

Methods Mol Biol. 2000;126:3-35. Review. No abstract available.

PMID:
10685400
43.

Bolus intravenous injection of phosphorothioate oligonucleotides causes hypotension by acting as alpha(1)-adrenergic receptor antagonists.

Iversen PL, Cornish KG, Iversen LJ, Mata JE, Bylund DB.

Toxicol Appl Pharmacol. 1999 Nov 1;160(3):289-96.

PMID:
10544063
44.

Characterization of alpha2 adrenergic receptor subtypes in human ocular tissue homogenates.

Bylund DB, Chacko DM.

Invest Ophthalmol Vis Sci. 1999 Sep;40(10):2299-306.

PMID:
10476796
45.

Alpha-2 adrenergic receptor functional coupling to G proteins in rat brain during postnatal development.

Happe HK, Bylund DB, Murrin LC.

J Pharmacol Exp Ther. 1999 Mar;288(3):1134-42.

PMID:
10027851
46.

Differential down-regulation of alpha-2 adrenergic receptor subtypes.

Heck DA, Bylund DB.

Life Sci. 1998;62(17-18):1467-72. Review.

PMID:
9585120
47.

The dose-response model for dioxin.

Byrd DM 3rd, Allen DO, Beamer RL, Besch HR Jr, Bylund DB, Doull J, Fleming WW, Fries A, Guengerich FP, Hornbrook R, Lasagna L, Lum BK, Michaelis EK, Morgan ET, Poland A, Rozman KK, Smith JB, Swanson HI, Waddell W, Wilson JD.

Risk Anal. 1998 Feb;18(1):1-2. No abstract available.

PMID:
9556441
48.

Synthesis and biological evaluation of [11C]MK-912 as an alpha2-adrenergic receptor radioligand for PET studies.

Shiue C, Pleus RC, Shiue GG, Rysavy JA, Sunderland JJ, Cornish KG, Young SD, Bylund DB.

Nucl Med Biol. 1998 Feb;25(2):127-33.

PMID:
9468027
49.

Mechanism of down-regulation of alpha-2 adrenergic receptor subtypes.

Heck DA, Bylund DB.

J Pharmacol Exp Ther. 1997 Sep;282(3):1219-27.

PMID:
9316829
50.

Characterization of alpha-2D adrenergic receptor subtypes in bovine ocular tissue homogenates.

Bylund DB, Iversen LJ, Matulka WJ, Chacko DM.

J Pharmacol Exp Ther. 1997 Jun;281(3):1171-7.

PMID:
9190850

Supplemental Content

Loading ...
Support Center